blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3323413

EP3323413 - PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB AND TRAMADOL [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  10.03.2023
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  31.07.2020
FormerGrant of patent is intended
Status updated on  13.04.2020
FormerExamination is in progress
Status updated on  09.12.2019
FormerRequest for examination was made
Status updated on  20.04.2018
FormerThe international publication has been made
Status updated on  20.01.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Yoo Young Pharm Co., Ltd.
93 Yooyoung Bldg.
Hyoryeong-ro
Seocho-gu
Seoul 06687 / KR
[2018/21]
Inventor(s)01 / KIM, Jung Ju
9-203
120 Seolleung-ro
Gangnam-gu
Seoul 06093 / KR
02 / LEE, Dong Min
906-2101
276 Dongtandaerosibeom-gil
Hwaseong-si Gyeonggi-do 18477 / KR
03 / KIM, Sun Kyoung
609-2409
393 Hyoseo-ro
Gyeyang-gu
Incheon 21125 / KR
 [2018/21]
Representative(s)Louis Pöhlau Lohrentz
Patentanwälte
Postfach 30 55
90014 Nürnberg / DE
[2018/21]
Application number, filing date16824623.929.06.2016
[2018/21]
WO2016KR06930
Priority number, dateKR2015009980814.07.2015         Original published format: KR 20150099808
[2018/21]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017010706
Date:19.01.2017
Language:KO
[2017/03]
Type: A1 Application with search report 
No.:EP3323413
Date:23.05.2018
Language:EN
[2018/21]
Type: B1 Patent specification 
No.:EP3323413
Date:02.09.2020
Language:EN
[2020/36]
Search report(s)International search report - published on:KR19.01.2017
(Supplementary) European search report - dispatched on:EP31.01.2019
ClassificationIPC:A61K31/415, A61K31/135, A61K47/38, A61K47/44, A61K47/36, A61K9/24
[2019/09]
CPC:
A61K9/209 (EP,US); A61K31/135 (EP,RU,US); A61K31/635 (CN);
A61K9/4866 (US); A61K31/133 (EP,US); A61K31/137 (CN);
A61K31/18 (EP,US); A61K31/415 (EP,RU,US); A61K47/14 (CN,RU);
A61K47/20 (CN); A61K47/26 (CN,RU); A61K47/32 (CN,US);
A61K47/36 (EP,US); A61K47/38 (EP,CN,RU,US); A61K47/44 (EP,CN,RU,US);
A61K9/4808 (US); A61P25/04 (EP); A61P29/00 (EP,CN,RU);
A61P43/00 (EP) (-)
C-Set:
A61K31/137, A61K2300/00 (CN);
A61K31/635, A61K2300/00 (CN)
Former IPC [2018/21]A61K31/415, A61K31/135, A61K47/38, A61K47/44, A61K47/36
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/21]
Extension statesBA18.01.2018
ME18.01.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT CELECOXIB UND TRAMADOL[2018/21]
English:PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB AND TRAMADOL[2018/21]
French:COMPOSITION PHARMACEUTIQUE CONTENANT DU CÉLÉCOXIB ET DU TRAMADOL[2018/21]
Entry into regional phase18.01.2018Translation filed 
18.01.2018National basic fee paid 
18.01.2018Search fee paid 
18.01.2018Designation fee(s) paid 
18.01.2018Examination fee paid 
Examination procedure18.01.2018Examination requested  [2018/21]
18.01.2018Date on which the examining division has become responsible
30.08.2019Amendment by applicant (claims and/or description)
12.12.2019Despatch of a communication from the examining division (Time limit: M02)
24.02.2020Reply to a communication from the examining division
14.04.2020Communication of intention to grant the patent
28.07.2020Fee for grant paid
28.07.2020Fee for publishing/printing paid
28.07.2020Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  02.06.2021  04.06.2021  ADMISSIBLE
Dehmel & Bettenhausen Patentanwälte PartmbB
Herzogspitalstr. 11
80331 München / DE
Opponent's representative
Peters, Hajo
Dehmel & Bettenhausen
Patentanwälte PartmbB
Herzogspitalstraße 11
80331 München / DE
 [2021/28]
Former [2021/27]
Opponent(s)01  02.06.2021   
Dehmel & Bettenhausen Patentanwälte PartmbB
Herzogspitalstr. 11
80331 München / DE
Opponent's representative
Dehmel, Albrecht
Dehmel & Bettenhausen
Patentanwälte PartmbB
Herzogspitalstraße 11
80331 München / DE
17.06.2021Invitation to proprietor to file observations on the notice of opposition
22.10.2021Reply of patent proprietor to notice(s) of opposition
24.10.2022Cancellation of oral proceeding that was planned for 01.12.2022
24.11.2022Date of despatch of rejection of opposition
01.12.2022Date of oral proceedings
04.12.2022Legal effect of rejection of opposition [2023/15]
Fees paidRenewal fee
28.06.2018Renewal fee patent year 03
26.06.2019Renewal fee patent year 04
31.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.06.2016
AL02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
MK02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
IE29.06.2021
LU29.06.2021
[2024/22]
Former [2023/33]HU29.06.2016
AL02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
IE29.06.2021
LU29.06.2021
Former [2023/30]AL02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
IE29.06.2021
LU29.06.2021
Former [2022/21]AL02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
IE29.06.2021
LU29.06.2021
Former [2022/18]AL02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
LU29.06.2021
Former [2022/08]AL02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/37]AL02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/36]AL02.09.2020
CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/28]AL02.09.2020
CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/25]AL02.09.2020
CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/22]CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/21]FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/10]FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
Former [2021/09]FI02.09.2020
LT02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
Former [2021/08]FI02.09.2020
LT02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
Former [2021/07]FI02.09.2020
LT02.09.2020
NO02.12.2020
Documents cited:Search[A]WO2009049405  (LABOPHARM INC [CA], et al) [A] 1-10 * paragraph [0045]; claims 1-12 *;
 [Y]US2009175939  (BOSSE PAUL [US], et al) [Y] 1-10 * paragraph [0164] - paragraph [0165]; claims 1-3, 8, 10 *;
 [Y]WO2015016695  (RAAM DE SAHUAYO S A DE C V LAB [MX]) [Y] 1-10* claim - *
International search[A]KR20040067969  (AMOREPACIFIC CORP) [A] 1-10 * See the entire document. *;
 [Y]KR20080104910  (HANA PHARM CO LTD [KR]) [Y] 1-10 * See claims 1-9. *;
 [A]KR20110122287  (SAMYANG HOLDINGS CORP [KR]) [A] 1-10* See abstract. *;
 [Y]KR20130069484  (SAMYANG BIOPHARMACEUTICALS [KR]) [Y] 2-7 * See claims 1-13. *;
 [Y]JP2014221797  (ESTEVE LABOR DR) [Y] 1-10 * See claims 1-13. *
OppositionKR20080104910
 WO2009049405
 US2009175939
 WO2011045075
 KR20130069484
 WO2015016695
 KR20150099808
    - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CELEBREX safely and effectively. See full prescribing information for CELEBREX", CELEBREX, (20180601), pages 1 - 22, XP055951645
    - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ULTRA ER ", ULTRAMER, (19950101), pages 1 - 37, XP055951647
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.